Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027963 · ClinicalTrials.gov registry record · Phase 3
Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00027963 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 100 participants.
The verdict
NCT00027963, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
RATIONALE: Gabapentin may be effective in relieving pain and other symptoms of peripheral neuropathy. It is not yet known if gabapentin is effective in treating peripheral neuropathy in cancer patients undergoing chemotherapy. PURPOSE: Randomized phase III trial to determine the effectiveness of gabapentin in treating pain and other symptoms of peripheral neuropathy in cancer patients undergoing chemotherapy.
Interventions
- OTHER placebo
- DRUG gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2002-02 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027963
The ClinicalTrials.gov registry entry for NCT00027963 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00027963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027963 about?
NCT00027963 is a clinical study titled "Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy". RATIONALE: Gabapentin may be effective in relieving pain and other symptoms of peripheral neuropathy. It is not yet known if gabapentin is effective in treating peripheral neuropathy in cancer patients undergoing chemotherapy. PURPOSE: Randomized phase III trial to determine the effectiveness of ga...
What is the current status of trial NCT00027963?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2002-02. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00027963?
The interventions under investigation include: placebo (OTHER), gabapentin (DRUG).
Who is sponsoring clinical trial NCT00027963?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.